Drug Trial Radar · NCT00496197
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
Last checked: Nov 20, 2026Latest source record: Oct 3, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
282
Actual
Start
Jul 2007
Primary completion
Jun 2010
Study completion Jun 2010
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 4, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to further evaluate the safety and effectiveness of intravenous anidulafungin (Eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis, which is a fungus infection of the blood or tissue. Currently the drug is approved for treatment using a daily dose of IV medication until 14 days after the fungus disappears from the blood. This study will evaluate the effectiveness of intravenous anidulafungin when it is administered for 5-28 days followed by oral antifungal medication. Study patients will be assessed for response to treatment throughout the study drug treatment period.
Conditions
- Candidiasis
Interventions
Eraxis (anidulafungin)Drug
Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
Diflucan (fluconazole)Drug
Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
Vfend (voriconazole)Drug
Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Global Response of Success or Failure (Based on Clinical and Microbiological Response) at End of Treatment (EOT)Time frame: End of Treatment (Day 5 up to Day 42)
Locations
43 sites in 2 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Little Rock, Arkansas
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
Newark, Delaware
Pfizer Investigational Site
Newark, Delaware
Pfizer Investigational Site
Wilmington, Delaware
Pfizer Investigational Site
Washington D.C., District of Columbia
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Orlando, Florida
Pfizer Investigational Site
Orlando, Florida
Pfizer Investigational Site
Orlando, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Springfield, Illinois
Pfizer Investigational Site
Springfield, Illinois
Pfizer Investigational Site
Springfield, Illinois
Pfizer Investigational Site
Springfield, Illinois
Pfizer Investigational Site
Baltimore, Maryland
Pfizer Investigational Site
Baltimore, Maryland
Pfizer Investigational Site
Detroit, Michigan
Pfizer Investigational Site
Detroit, Michigan
Pfizer Investigational Site
Royal Oak, Michigan
Pfizer Investigational Site
Minneota, Minnesota
Pfizer Investigational Site
Butte, Montana
Pfizer Investigational Site
Camden, New Jersey
Pfizer Investigational Site
Albany, New York
Pfizer Investigational Site
Buffalo, New York
Pfizer Investigational Site
Rochester, New York
Pfizer Investigational Site
Greenville, North Carolina
Pfizer Investigational Site
Greenville, North Carolina
Pfizer Investigational Site
Portland, Oregon
Pfizer Investigational Site
Philadelphia, Pennsylvania
Pfizer Investigational Site
Pittsburgh, Pennsylvania
Pfizer Investigational Site
West Reading, Pennsylvania
Pfizer Investigational Site
Charleston, South Carolina
Pfizer Investigational Site
Houston, Texas
Pfizer Investigational Site
Seoul, South Korea
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.